header logo image


Page 581«..1020..580581582583..590600..»

Eye care treatment centres set up across Scotland after 3m investment – Aberdeen Evening Express

April 25th, 2020 7:54 am

New centres have been set up to help Scots who suffer emergency eye problems during the coronavirus pandemic.

Health Secretary Jeane Freeman has announced 3 million of Scottish Government cash towards the creation of more than 50 emergency eye care treatment centres.

These are being set up in all health board areas, while hubs in NHS Grampian and NHS Forth Valley will also benefit from new technology.

Live video and audio feeds between the centres and consultants in hospitals are being used to allow more patients to be immediately diagnosed and treated.

Patients, who will have an initial telephone consultation, will be referred to optometrists if needed.

Ms Freeman said: While services have changed dramatically over the last few weeks, my message is clear if you are worried about your health in any way, please get in touch with your GP.

The same applies to your vision if you have experienced any problems with your sight, please contact your local high street optician as soon as possible.

She thanked health boards and eye care specialists for the excellent collaboration in establishing, at pace, more than 50 emergency eye care treatment centres across Scotland to manage patients without Covid-19 symptoms who need an emergency face-to-face consultation.

The Health Secretary added: I am pleased to see some NHS boards are also using innovative new tele-ophthalmology technology.

This means that more patients can be immediately diagnosed and treated in a community setting while gaining an expert opinion from the secondary care ophthalmology team.

Here is the original post:
Eye care treatment centres set up across Scotland after 3m investment - Aberdeen Evening Express

Read More...

Peterborough residents urged to keep an eye on vision and hearing problems during lockdown – Peterborough Telegraph

April 25th, 2020 7:54 am

While Specsavers in Peterborough are closed for all routine eye and hearing tests at the moment, they are still open to provide essential care and to support local key workers.

Customers are being encouraged to contact their local store if they need urgent support with a visual problem, or if they have issues with their glasses, contact lenses or hearing aids.

If anyone is required to attend the store, they will be asked to do so and key workers will be prioritised. Any face to face contact will be minimal and will be handled in line with current Government guidelines.

Recently, the team were able to assist a vulnerable customer who was unable to drop off his hearing aids in store for a repair, as he was self-isolating. A team member offered to take a look at the customers hearing aids at his home free of charge, carrying out the necessary clean and repairs on the equipment all whilst wearing full PPE.

After cleaning the debris out of the customers hearing aids, the team member even returned for a second visit later on to drop off some spare drying capsules to the customer who had run out.

Chintu Patel, store director at Specsavers in Peterborough, said: We want the local community to know that, while we are closed for routine appointments at the present time, we are still very much here to support people with their essential eye and hearing care needs, and to make sure they can see and hear healthily whilst staying at home.

Eye and ear health remains really important, and providing the local community and vulnerable people with access to professional optical and audiology services whilst lockdown continues, is why were determined to stay operational. Please do give us a call if you need assistance because were more than happy to help.

Specsavers teams are classed as key workers to provide urgent and essential eye care to those who need it. This includes supporting other key workers who couldnt function without their help and people who would come to harm without their health expertise, especially where the usual hospital services and NHS facilities are being prioritised for the fight against COVID-19.

Customers can also visit Facebook to have any questions on their sight and hearing answered by expert optometrists and audiologists,

here: https://www.facebook.com/groups/SpecsaversAskTheExpert/?fref=nf.

See the rest here:
Peterborough residents urged to keep an eye on vision and hearing problems during lockdown - Peterborough Telegraph

Read More...

Focus on Eyes: Cocaine, meth, other vices affect eyes more than you know – Florida Today

April 25th, 2020 7:54 am

Dr. Frederick Ho, Special to FLORIDA TODAY Published 6:29 a.m. ET April 21, 2020

Smoking, binge drinking and illicit drug use can lead to serious eye problems.(Photo: Getty images)

An unhealthy lifestyle translates into many health problems.

Smoking, binge drinking and illicit drug use are known to cause cancer, diabetes, heart disease, lung damage, stroke and death. They can also lead to serious eye problems.

Cigarette smoking remains a major health issue despite of years of health warnings and public awareness campaigns.

Smoking has been linked to early development of macular degeneration and cataracts.

Dr. Frederick Ho(Photo: FLORIDA TODAY FILE)

Compared to non-smokers, people who smoke a pack or more per day are two-to-three times more likely to develop macular degeneration an aging condition in the retina, affecting the central vision.

The inhaled substances in cigarette smoke constrict the blood vessels and promote blood clot formation in the retina and optic nerves.

Partial to almost complete blindness happens when there is thrombosis, or blood clot, in the central retinal artery, which is the main artery that supplies blood, oxygen and nutrients to the retina.

Smoking increases the risk of ischemia, or stroke, in the optic nerve, which transmits the images from the eye to the brain, resulting significant permanent visual loss.

About one-in-six adult Americans binge drinks about four times a month, consuming about eight drinks each time.

There is a well-established linkage between Type 2 diabetes and excessive alcohol consumption.

The most serious ocular complications of diabetes is diabetic retinopathy. The diabetes-damaged retina develops hemorrhages and swelling, resulting in visual loss.

Alcohol abuse increases the incidence of early onset of cataracts and macular degeneration.

More: Focus on Eyes: Chinese ophthalmologist warned about COVID-19 outbreak

More: Focus on Eyes: Celebrating America's first black ophthalmologist

More: Focus on Eyes: What does it mean to have 20/20 vision

Methanol, or wood alcohol, in contaminated moonshine damages the optic nerve, and if untreated,the person will suffer partial to total blindness.

Ocular trauma with visual loss is too often seen with alcohol intoxication.

Illegal substance abuse is at the extreme end of vices.

It is estimated about 10 percent of adults use illegal drugs.

There are many deleterious effects to the eyes.

Intranasal cocaine use is particularly damaging and potentially leading to acute attack of angle closure glaucoma, retinal hemorrhages and optic nerve damage.

Smoking crack cocaine is associated with infection and diminished blood flow to the retina.

Methamphetamine use is known to cause infection in the cornea which is the transparent tissue in front of the eye.

Retinal inflammation is also seen in methamphetamine use.

Intravenous drug abuse introduces infection to the eyes and particles clotting the blood vessels in the retina and the optic nerve.

Many people assume their vices will get their eyes red and eyelids droopy.

In fact, they can suffer from many sight threatening complications.

Hopefully, this will motivatethem to give up their vices and adopt healthy habits.

Dr. Frederick Ho,the medical director of Atlantic Eye MD and Atlantic Surgery and Laser Center, is a board certified ophthalmologist. Atlantic Eye MDis located at 8040 N. Wickham Road in Melbourne. To make an appointment please call (321) 757-7272. To learn more visit AtlanticEyeMD.com.

Read or Share this story: https://www.floridatoday.com/story/life/wellness/2020/04/21/focus-eyes-cocaine-meth-other-vices-affect-eyes-more-than-you-know/5164034002/

Read the rest here:
Focus on Eyes: Cocaine, meth, other vices affect eyes more than you know - Florida Today

Read More...

Glaucoma can be successfully treated with gene therapy – Telangana Today

April 25th, 2020 7:54 am

London:A common eye condition, glaucoma, could be successfully treated with a single injection using gene therapy, which would improve treatment options, effectiveness and quality of life for many patients, say researchers.

Glaucoma affects over 64 million people worldwide and is a leading cause of irreversible blindness. It is usually caused by fluid building up in the front part of the eye, which increases pressure inside the eye and progressively damages the nerves responsible for sight.

Current treatments include either eye drops, laser or surgery, all of which have limitations and disadvantages.

At present, there is no cure for glaucoma, which can lead to loss of vision if the disease is not diagnosed and treated early, said study researcher Dr Colin Chu from the University of Bristol in the UK.

For the findings, published in the journal Molecular Therapy, the research team tested a new approach that could provide additional treatment options and benefits.

The researchers designed a gene therapy and demonstrated proof of concept using experimental mouse models of glaucoma and human donor tissue.

The treatment targeted part of the eye called the ciliary body, which produces the fluid that maintains pressure within the eye.

Using the latest gene-editing technology called CRISPR, a gene called Aquaporin 1 in the ciliary body was inactivated leading to reduced eye pressure.

We hope to advance towards clinical trials for this new treatment in the near future. If its successful it could allow a long-term treatment of glaucoma with a single eye injection, which would improve the quality of life for many patients whilst saving the NHS time and money, Chu said

The researchers are currently in discussion with industry partners to support further laboratory work and rapidly progress this new treatment option towards clinical trials.

Read this article:
Glaucoma can be successfully treated with gene therapy - Telangana Today

Read More...

Michelle Cretella is Back – Along With Her Sophistry – The Slowly Boiled Frog

April 25th, 2020 7:53 am

If Dr. Michelle Cretella disagrees with the science then she should publish. She never has and she never will because she can't.

The pediatrician that Murphee is referring to is Michelle Cretella, executive director of American College of Pediatricians (ACPeds). Southern Poverty Law Center deems ACPeds to be an anti-LGBTQ hate group as well.

Before we wander into the text it is important to understand that Michelle Cretella's point of view is not as a physician. Not at all. Cretella is a Catholic extremist. Cretella conforms to Vatican doctrine, no matter how idiotic that might be and, according to the Vatican, transgender people do not really exist.

As for Murphee's title, insanity is substituting religious dogma for medical science. The dogma emanates from celibate prelates who are theologians and catechists with no training or experience in medical science.

And we begin

Junk scientist! they shout. Hater!

All lies.

She is, however, a formidable foe of the transgender activist agenda and in its view, a villain to be destroyed.

Furthermore, Michelle Cretella is not a foe of mythical activists. Rather, Cretella is a foe of gender-affirming care which is the clinical standard of care according to her former peer group, the American Academy of Pediatrics.

Michelle Cretella is in a battle of her own making. The two sides are religious dogma vs. medical science. But it is not that simple. Cretella is intellectually dishonest. She is promoting faith-based Catholic doctrine as if it were evidence-based science. That constitutes the big lie.

Speaking of bullshit

I have no quarrel with what Mr. Murphee calls biblical truths other than the fact that scripture might have been accepted as truth when it was written but is not scientifically truthful today. Even then, Cretella's religious beliefs are hers to hold. Yet, she is not entitled to promote religious beliefs as science.

Cretella is claiming, essentially, that a sinister conspiracy to intentionally damage children exists. Doctors and educators and the media and secular people and They are allin on it.

If she believes that she has a better treatment plan for acute pediatric gender dysphoria then she should do what experts in this area routinely do which is to publish findings to reputable academic journals. She never has. She cannot.

As for surgery (which Murphee presents for shock value), about 30% of transgender people have gender-affirming surgery. At least a year of behavioral health therapy is required for a patient to qualify. Is 30% many?

No transgender person gives a flying fuck whether or not Murphee or Cretella approve of them. Transgender people are entitled to common courtesy. In polite society, we address people as they choose to be addressed. Trans people expect to be addressed according to their gender.

Misgendering trans people particularly trans kids does violence to them. It is gratuitously cruel to misgender trans people as a means of demonstrating disapproval. Doing so is a form of arrogance.

Misgendering is a false message that an individual's approval has been solicited (it has not). Then that individual feels compelled to demonstrate that their approval is withheld. It is entirely unnecessary.

Murphee and Cretella believe two things about me (and then some): They believe that, because I am gay, I am objectively disordered. Because I am Jewish they believe that I am destined to go to Hell.

I really do not care what they believe. If they call me a faggot kike that gets my attention. Belief and conduct are two different things.Is expecting people to be polite really so burdensome?

Referring to the construct of gender as separate from natal sex:

Again, if Cretella disagrees with the science then she should publish. Comments at one of AFA's outlets is not the equivalent of publishing to a reputable academic journal.

Cretella has never published because her views are based on religion in contrast to science. She is also a demagogue. No one is attacking children and children are not candidates for surgery. Furthermore, Cretella seeks to substitute her religious judgment for that of clinicians and parents.

Let us review what Cretella calls an attack. Prepubescent children transition if a) they are in distress and; b) if transitioning offers relief. Transitioning means gender-conforming clothes and hair. No drugs whatsoever.After entering puberty (Tanner stage 2 or 3) adolescents might be provided with puberty blockers which are fully reversible according to the Endocrine Society.

According to the Mayo Clinic, for children who have gender dysphoria, suppressing puberty might:

If an adolescent child stops taking GnRH analogues, puberty will resume.

The administration of hormones is not gratuitous chemistry. It requires a clinical evaluation, a mental health evaluation, informed consent and parental consent. Consent means a demonstrable understanding of risks and benefits.

A simple and simplistic comment triggers a verbose rebuttal but we all need to separate science from religious ideology.

Off into a land where reality is optional

Thats simply insane! Cretella exclaimed. Its contrary to reality and to a Judeo-Christian worldview. Sex is determined. Its not assigned. Its determined at fertilization. If you have a Y chromosome, you will go down the male pathway. If youre missing the Y chromosome, youll go down the female pathway.

Cretella is being dishonest. She knows perfectly well that sex assigned at birth is a means of communicating the difference between natal sex from gender. It is applicable to a very small percentage of the population.

A feeble attempt to claim that science is on their side

As adults, physical differences between men and women account for many of their contrasting thought patterns and behaviors, even if they agree in principle on important areas of life, e.g., parenting.

This all goes on for several paragraphs. Cretella uses the opportunity to take a dishonest swipe at marriage equality (which I will ignore) and there is this:

The worst side effects of puberty blocking may include brittle bones, obesity, testicular cancer, memory problems, and [if combined with cross-sex hormones] permanent sterilization, Cretella reported. This is child abuse.

Parents and the adolescent provide informed consent. They are aware of the potential side effects but make a considered judgment that the benefits outweigh the risks. Cretella has no experience in this area. Cretella has minimal training in endocrinology.

Notice how Cretella doesn't establish what that real help is. Children have rights too including the right to be treated according to the best available medical science.

Look! It's a bullshit kabob. Yum!

At long last the witch and her fluffer identify this as a religious issue

To declare that our bodies dont matter, she added, is diametrically opposed to Christian theology. The Incarnate Word. God how did He save? He saved us by taking on a human body. This is significant.

To believe our body is just this container, and it doesnt matter thats in line with reincarnation, Hinduism, Buddhism! It is the age-old conflict between a pagan worldview and a Christian one.

Related content:

Go here to read the rest:
Michelle Cretella is Back - Along With Her Sophistry - The Slowly Boiled Frog

Read More...

Did this virus come from a lab? Maybe not but it exposes the threat of a biowarfare arms race – Raw Story

April 25th, 2020 7:53 am

There is no scientific evidencethat the novel coronavirus was bioengineered, but its origins are not entirely clear. Deadly pathogens discovered in the wild can be studied in secret in biowarfare labs and sometimes made more dangerous. That possibility, and other plausible scenarios, have been incorrectly dismissed in remarks by some scientists andgovernment officials, and in the coverage of most major media outlets.

Regardless of the source of this pandemic, there is considerable documentation that a global biological arms race going on outside of public view could produce even more deadly pandemics in the future.

While much of the media and political establishment have minimized the threat from such lab work, some hawks on the American right like Sen. Tom Cotton, R-Ark., have singled outChinese biodefense researchers as uniquely dangerous.

But there is every indication that U.S. lab work is every bit as threatening as that in Chinese labs. American labs also operate insecret, and are also known to beaccident-prone.

The current dynamics of the biological arms race have been driven by U.S. government decisions that extend back decades. In December 2009, Reuters reported that the Obama administration was refusing even to negotiate the possible monitoring of biological weapons.

Much of the left in the U.S. now appears unwilling to scrutinize the origin of the pandemic or the wider issue of biowarfare perhaps because portions of the anti-Chinese right have been sovocal in making unfoundedallegations.

Governments that participate in such biological weapon research generally distinguish between biowarfare and biodefense, as if to paint such defense programs as necessary. But this is rhetorical sleight-of-hand; the two concepts are largely indistinguishable.

Biodefense implies tacit biowarfare, breeding more dangerous pathogens for the alleged purposeof finding a way tofightthem. While this work appears to have succeeded in creating deadly and infectious agents, including deadlier flu strains, such defense research is impotent in its ability to defend us from this pandemic.

The legal scholar who drafted the main U.S. law on the subject, Francis Boyle, warned in his 2005 book Biowarfare and Terrorism that an illegal biological arms race with potentially catastrophic consequences was underway, largely driven by the U.S. government.

For years,many scientistshave raised concerns regarding bioweapons/biodefense lab work, and specifically aboutthe fact that huge increases in funding have taken place since 9/11. This was especially true afterthe anthrax-by-mail attacks that killed five people in the weeks after 9/11, which the FBI ultimately blamed on a U.S. government biodefense scientist.A 2013 study found that biodefense funding since2001 hadtotaled at least $78 billion, and more has surely been spent since then. This has led to aproliferation of laboratories, scientists and new organisms, effectively setting off a biological arms race.

Following the Ebola outbreak in west Africa in 2014, the U.S. governmentpaused fundingfor what are known as gain-of-function research on certain organisms. This work actually seeks to make deadly pathogensdeadlier, in some cases making pathogens airborne thatpreviously were not. With little notice outside the field, the pause on such research was lifted in late 2017.

During this pause, exceptions for funding were made for dangerous gain-of-function lab work. This included work jointly done by U.S. scientists from the University of North Carolina, Harvard and the Wuhan Institute of Virology. This work which had funding from USAID and EcoHealth Alliance not originally acknowledged was published in2015 in Nature Medicine.

A different Nature Medicine article about the origin of the current pandemic,authored by five scientists andpublished on March 17,has been touted by major media outlet and some officials including current National Institutes of Health directorFrancis Collins as definitively disproving a lab origin for the novel coronavirus. That journal article, titled The proximal origin of SARS-CoV-2, stated unequivocally: Our analyses clearly show that SARS-CoV-2 is not a laboratory construct or a purposefully manipulated virus. This is a subtly misleading sentence. While the scientists state that there is no known laboratory signature in the SARS-Cov-2 RNA, their argument fails to take account of other lab methods that could have created coronavirus mutations without leaving such a signature.

Indeed, there is also thequestion of conflict of interest in the Nature Medicine article. Some of the authors of that article, as well as aFebruary 2020Lancet letter condemning conspiracy theories suggesting that COVID-19 does not have a natural origin which seemed calculated to minimize outside scrutiny of biodefense lab work have troubling ties to thebiodefense complex,as well as to the U.S. government. Notably, neither of these articles makes clear that a virus can have a natural originand then be captured and studied in a controlled laboratory setting before being let loose, either intentionally or accidentallywhichis clearly a possibility in the case of the coronavirus.

Facts as rumors

This reporter raised questions about the subject at a news conference with a Center for Disease Control (CDC) representative at the now-shuttered National Press Club on Feb. 11. I asked if it was a complete coincidence that the pandemic had started in Wuhan, the only place in China with a declared biosafety level 4 (BSL4) laboratory. BSL4 laboratories have the most stringent safety mechanisms, but handle the most deadly pathogens. As I mentioned, it was oddthat the ostensible origin of the novel coronavirus was bat caves in Yunnan province more than 1,000 miles from Wuhan. I noted that gain-of-function lab work can results in more deadly pathogens, and that major labs, including some in the U.S., have had accidental releases.

CDC Principal Deputy Director Anne Schuchat saidthatbased on the information she had seen, the virus was of zoonotic origin. She also stated, regarding gain-of-function lab work, that it is important to protect researchers and their laboratory workers as well as the community around them and that we use science for the benefit of people.

I followed up by asking whether an alleged natural origin did not preclude the possibility that this virus came through a lab, since a lab could have acquired a bat virus and been working on it. Schuchat replied to the assembled journalists that it is very common for rumors to emerge that can take on life of their own, but did not directly answer the question. She noted that in the 2014 Ebola outbreak some observers had pointed to nearby labs as the possible cause, claiming this was a key rumor that had to be overcome in order to help control the outbreak. She reiterated: So based on everything that I know right now, I can tell you the circumstances of the origin really look like animals-to-human. But your question, I heard.

This is no rumor. Its a fact: Labs work with dangerous pathogens. The U.S. and China each have dual-use biowarfare/biodefense programs. China has major facilities at Wuhan a biosafety level 4 lab and a biosafety level 2 lab. There are leaks from labs. (See Preventing a Biological Arms Race, MIT Press, 1990, edited by Susan Wright; also, a partial review in Journal of International Law from October 1992.)

Much of the discussion of this deadly serious subject is marred with snark that avoids or dodges the gain-of-function question. ABC ran a story on March 27 titled Sorry, Conspiracy Theorists. Study Concludes COVID-19 Is Not a Laboratory Construct.' That story did not address the possibility that the virus could have been found in the wild, studied in a lab and thenreleased.

On March 21, USA Today published a piece headlined Fact Check: Did the Coronavirus Originate In a Chinese Laboratory? and rated it FALSE.

That USA Today story relied ona widely cited Feb.17 piece inthe Washington Post, titled Tom Cotton keeps repeating a coronavirus conspiracy theory that was already debunked. That article quoted public comments fromRutgers University professor of chemical biology Richard Ebright, but out of context and only in part. Specifically, the story quoted from Ebrights tweet that the coronavirus was not an engineered bioweapon. In fact, his full quote included the clarification that the virus could have entered human population through lab accident. (An email requesting clarification sent toPost reporterPaulina Firoziwas met with silence.)

Bioengineered From a lab

Other pieces in the Post since then (some heavily sourced to U.S. government officials) have conveyed Ebrights thinking, but it gets worse. In a private exchange, Ebright who, again, has said clearly that the novel coronavirus was not technically bioengineered using known coronavirus sequences stated that other forms of lab manipulation could have beenresponsible for the current pandemic. This runs counter to much reporting, which is perhaps too scientifically illiterate to perceive the difference.

In response to the suggestion that the novel coronavirus could have come about through various methodsbesides bioengineering made by Dr. Meryl Nass, who has done groundbreaking work on biowarfareEbright responded in an email:

The genome sequence of SARS-CoV-2 has no signatures of human manipulation.

This rules out the kinds of gain-of-function (GoF) research that leave signatures of human manipulation in genome sequences (e.g., use of recombinant DNA methods to construct chimeric viruses), but does not rule out kinds of GoF research that do not leave signatures (e.g., serial passage in animals). [emphasis added]

Very easy to imagine the equivalent of the Fouchiers 10 passages in ferrets with H5N1 influenza virus, but, in this case, with 10 passages in non-human primates with bat coronavirus RaTG13 or bat coronavirus KP876546.

That last paragraph is very important. It refersto virologist Ron Fouchier of the Erasmus Medical Center in Rotterdam, who performed research on intentionally increasing rates of viralmutation rate by spreading a virus from one animal to another in a sequence.The New York Times wrote about this in an editorial in January 2012, warning of An Engineered Doomsday.

Now scientists financed by the National Institutes of Health have created a virus that could kill tens or hundreds of millions of people if it escaped confinement, the Times wrote. The story continued:

Working with ferrets, the animal that is most like humans in responding to influenza, the researchers found that a mere five genetic mutations allowed the virus to spread through the air from one ferret to another while maintaining its lethality. A separate study at the University of Wisconsin, about which little is known publicly, produced a virus that is thought to be less virulent.

The word engineering in the New York Times headline is technically incorrect, sincepassing a virus through animals is not genetic engineering. This same distinction has hindered some from understanding the possible origins of the current pandemic.

Fouchiers flu work, in which an H5N1 virus was made more virulent by transmitting it repeatedly between individual ferrets, briefly sent shockwaves through the media. Locked up in the bowels of the medical faculty building here and accessible to only a handful of scientists lies a man-made flu virus that could change world history if it were ever set free, wrote Science magazine in 2011 in a story titled Scientists Brace for Media Storm Around Controversial Flu Studies. It continues:

The virus is an H5N1 avian influenza strain that has been genetically altered and is now easily transmissible between ferrets, the animals that most closely mimic the human response to flu. Scientists believe its likely that the pathogen, if it emerged in nature or were released, would trigger an influenza pandemic, quite possibly with many millions of deaths.

In a 17th floor office in the same building, virologist Ron Fouchier of Erasmus Medical Center calmly explains why his team created what he says is probably one of the most dangerous viruses you can make and why he wants to publish a paper describing how they did it. Fouchier is also bracing for a media storm. After he talked to ScienceInsider yesterday, he had an appointment with an institutional press officer to chart a communication strategy.

Fouchiers paper is one of two studies that have triggered an intense debate about the limits of scientific freedom and that could portend changes in the way U.S. researchers handle so-called dual-use research: studies that have a potential public health benefit but could also be useful for nefarious purposes like biowarfare or bioterrorism.

Despite objections, Fouchiers article was published by Science in June 2012. Titled Airborne Transmission of Influenza A/H5N1 Virus Between Ferrets, it summarized how Fouchiers research team made the pathogen more virulent:

Highly pathogenic avian influenza A/H5N1 virus can cause morbidity and mortality in humans but thus far has not acquired the ability to be transmitted by aerosol or respiratory droplet (airborne transmission) between humans. To address the concern that the virus could acquire this ability under natural conditions, we genetically modified A/H5N1 virus by site-directed mutagenesis and subsequent serial passage in ferrets. The genetically modified A/H5N1 virus acquired mutations during passage in ferrets, ultimately becoming airborne transmissible in ferrets.

In other words, Fouchiers research took a flu virus that did not exhibit airborne transmission, then infected a number of ferrets until it mutated to the point that it was transmissible by air.

In thatsame year, 2012, asimilar studyby Yoshihiro Kawaoka of the University of Wisconsin was published in Nature:

Highly pathogenic avian H5N1 influenza A viruses occasionally infect humans, but currently do not transmit efficiently among humans. Here we assess the molecular changes that would allow a virus to be transmissible among mammals. We identified a virus with four mutations and the remaining seven gene segments from a 2009 pandemic H1N1 virus that was capable of droplet transmission in a ferret model.

In 2014, Marc Lipsitch of Harvard and Alison P. Galvani of Yale wrote regarding Fouchier and Kawaokas work:

Recent experiments that create novel, highly virulent and transmissible pathogens against which there is no human immunity are unethical they impose a risk of accidental and deliberate release that, if it led to extensive spread of the new agent, could cost many lives. While such a release is unlikely in a specific laboratory conducting research under strict biosafety procedures, even a low likelihood should be taken seriously, given the scale of destruction if such an unlikely event were to occur. Furthermore, the likelihood of risk is multiplied as the number of laboratories conducting such research increases around the globe.

Given this risk, ethical principles, such as those embodied in the Nuremberg Code, dictate that such experiments would be permissible only if they provide humanitarian benefits commensurate with the risk, and if these benefits cannot be achieved by less risky means.

We argue that the two main benefits claimed for these experiments improved vaccine design and improved interpretation of surveillance are unlikely to be achieved by the creation of potential pandemic pathogens (PPP), often termed gain-of-function (GOF) experiments.

There may be a widespread notion that there is scientific consensus that the pandemic did not come out of a lab. But in factmany of the most knowledgeable scientists in the field are notably silent. This includes Lipsitch at Harvard, Jonathan A. King at MITand many others.

Just last year, Lynn Klotz of the Center for Arms Control and Non-Proliferation wrote a paperin the Bulletin of the Atomic Scientistsentitled Human Error in High-biocontainment Labs: A Likely Pandemic Threat. Wrote Klotz:

Incidents causing potential exposures to pathogens occur frequently in the high security laboratories often known by their acronyms, BSL3 (Biosafety Level 3) and BSL4. Lab incidents that lead to undetected or unreported laboratory-acquired infections can lead to the release of a disease into the community outside the lab; lab workers with such infections will leave work carrying the pathogen with them. If the agent involved were a potential pandemic pathogen, such a community release could lead to a worldwide pandemic with many fatalities. Of greatest concern is a release of a lab-created, mammalian-airborne-transmissible, highly pathogenic avian influenza virus, such as the airborne-transmissible H5N1 viruses created in the laboratories of Ron Fouchier in the Netherlands and Yoshihiro Kawaoka in Madison, Wisconsin.

Crazy, dangerous

Boyle, a professor of international law at the University of Illinois, has condemned Fouchier, Kawaoka and others including at least one of the authors of the recent Nature Medicine article in the strongest terms, calling such work a criminal enterprise. While Boyle has been embroiled in numerous controversies, hes been especially dismissed by many on this issue. The fact-checking websiteSnopeshas described him as a lawyer with no formal training in virology without noting that he wrote the relevant U.S. law.

As Boyle saidin 2015:

Since September 11, 2001, we have spent around $100 billion on biological warfare. Effectively we now have an Offensive Biological Warfare Industry in this country that violates theBiological Weapons Conventionand myBiological Weapons Anti-Terrorism Act of 1989.

The law Boyle drafted states: Whoever knowingly develops, produces, stockpiles, transfers, acquires, retains, or possesses any biological agent, toxin, or delivery system for use as a weapon, or knowingly assists a foreign state or any organization to do so, shall be fined under this title or imprisoned for life or any term of years, or both. There is extraterritorial Federal jurisdiction over an offense under this section committed by or against a national of the United States.

Boyle also warned:

Russia and China have undoubtedly reached the same conclusions I have derived from the same open and public sources, and have responded in kind. So what the world now witnesses is an all-out offensive biological warfare arms race among the major military powers of the world: United States, Russia, Britain, France, China, Israel, inter alia.

We have reconstructed the Offensive Biological Warfare Industry that we had deployed in this county before its prohibition by the Biological Weapons Convention of 1972, described by Seymour Hersh in his groundbreaking expose Chemical and Biological Warfare: Americas Hidden Arsenal. (1968)

Boyle now states that he has been blackballed in the media on this issue, despite his having written the relevant statute. The group he worked with on the law, the Council for Responsible Genetics, went under several years ago, making Boyles views against biodefense even more marginal as government money for dual use work poured into the field and criticswithin the scientific community have fallen silent. In turn, his denunciationshave grown more sweeping.

In the 1990 book Preventing a Biological Arms Race, scholar Susan Wright argued that current laws regarding bioweapons were insufficient, as there were projects in which offensive and defensive aspects can be distinguished only by claimed motive. Boyle notes, correctly, that current law he drafted does not makean exception for defensive work, but only for prophylactic, protective or other peaceful purposes.

While Boyle is particularly vociferous in his condemnations, he is not alone. There has been irregular, but occasional media attention to this threat. The Guardian ran a piece in 2014,Scientists condemn crazy, dangerous creation of deadly airborne flu virus, afterKawaoka created a life-threatening virus that closely resembles the 1918 Spanish flu strain that killed an estimated 50m people:

The work they are doing is absolutely crazy. The whole thing is exceedingly dangerous, said Lord May, the former president of the Royal Society and one time chief science adviser to the UK government. Yes, there is a danger, but its not arising from the viruses out there in the animals, its arising from the labs of grossly ambitious people.

Boylescharges beginning early this yearthat the coronavirus was bioengineered allegationsrecently mirrored by French virologist andNobel laureate Luc Montagnier have not been corroborated by any publicly produced findings of any U.S. scientist. Boyle even charges that scientists like Ebright, who is at Rutgers, arecompromised because the university got abiosafety level 3 lab in 2017though Ebright is perhaps the most vocal eminent critic of this research, among U.S. scientists. These and other controversies aside, Boyles concerns about the dangers of biowarfare arelegitimate; indeed, Ebright shares them.

Some of the most vocal voices to discuss the origins of the novel coronavirushave been eager to minimizethe dangers of lab work, or have focused almost exclusively on wet markets or exotic animals as the likely cause.

The media celebrated Laurie Garrett, the Pulitzer Prizewinning author and former senior fellow at the Council on Foreign Relations, when she declared on Twitter on March 3 (in a since-deleted tweet)that the origin of the pandemic was discovered: Its pangolins. #COVID19 Researchers studied lung tissue from 12 of the scaled mammals that were illegally trafficked in Asia and found #SARSCoV2 in 3. The animals were found in Guangxi, China. Another virus+ smuggled sample found in Guangzhou.

She was swiftly corrected by Ebright: Arrant nonsense. Did you even read the paper? Reported pangolin coronavirus is not SARS-CoV-2 and is not even particularly close to SARS-CoV-2. Bat coronavirus RaTG13 is much closer to SARS-CoV-2 (96.2% identical) than reported pangolin coronavirus (92.4% identical). He added: No reason to invoke pangolin as intermediate. When A is much closer than B to C, in the absence of additional data, there is no rational basis to favor pathway A>B>C over pathway A>C. When someone asked what Garrett was saying, Ebright responded: She is saying she is scientifically illiterate.

The following day, Garrett corrected herself (without acknowledging Ebright): I blew it on the #Pangolins paper, & then took a few hours break from Twitter. It did NOT prove the species = source of #SARSCoV2. Theres a torrent of critique now, deservedly denouncing me & my posting. A lot of the critique is super-informative so leaving it all up 4 while.

At leastone Chinese governmentofficialhas respondedto the allegation that the labs in Wuhan could be the source for the pandemic by alleging that perhaps the U.S. isresponsibleinstead. In American mainstreammedia, that has been reflexivelytreated as evenmore ridiculousthan the original allegation that the virus could havecome froma lab.

Obviouslythe Chinese governmentsallegations should not be taken at face value, but neither should U.S. government claims especially considering that U.S. government labs were the apparent source for theanthrax attacks in 2001. Those attacks sent panic through the U.S. and shut down Congress, allowing the Bushadministration to enact the PATRIOT Act and ramp up the invasions of Afghanistan and Iraq. Indeed, in October2001, media darlings like Richard Butler and Andrew Sullivan propagandizedfor war with Iraq because of the anthrax attacks. (Although it turned out that neither Iraq nor al-Qaida was involved.)

The 2001 anthrax attacks also provided muchof the pretext forthe surge in biolab spending since then, even though they apparently originated in a U.S. or U.S.-allied lab. Indeed, thoseattacks remain shrouded in mystery.

The U.S. government has also come up withelaborate cover stories to distract from its bioweapons work. For instance, the U.S. government infamously claimed the 1953 death of Frank Olson, a scientist at Fort Detrick, Maryland, was anLSD experiment gone wrong;it now appears to have been an execution to cover up for U.S.biological warfare.

Regardless of the cause of the current pandemic, these biowarfare/biodefense labs need far more scrutiny. The call to shut them down by Boyle and others needs to be clearly heard and light must be shone on precisely what research is being conducted.

The secrecy of these labs may prevent us ever knowing with certainty the origins of the current pandemic. It could have been a lab release, presumably accidental, or it could have been a zoonotic, or animal-to-human, infection

What we do know is this lab work comes with real dangers. One might make a comparison to climate change: We cannot attribute an individual hurricane to man-made climate disruption,yet science tells us that human activity makes stronger hurricanes more likely. Thatbrings us back to the imperative to cease the kinds of activities thatproduce such dangers in the first place.

If that doesnt happen, the people of the planet will be at the mercy of the machinations and mistakes of state actors who are playing with fire for their geopolitical interests.

Sam Husseini is a writer and political activist. He is communications director of the Institute for Public Accuracy, a Washington-based nonprofit that promotes progressive experts as alternative sources for mainstream media reporters. He tweets @samhusseini.

then let us make a small request. The COVID crisis has cut advertising rates in half, and we need your help. Like you, we here at Raw Story believe in the power of progressive journalism. Raw Story readers power David Cay Johnstons DCReport, which we've expanded to keep watch in Washington. Weve exposed billionaire tax evasion and uncovered White House efforts to poison our water. Weve revealed financial scams that prey on veterans, and legal efforts to harm workers exploited by abusive bosses. And unlike other news outlets, weve decided to make our original content free. But we need your support to do what we do.

Raw Story is independent. Unhinged from corporate overlords, we fight to ensure no one is forgotten.

We need your support in this difficult time. Every reader contribution, whatever the amount, makes a tremendous difference. Invest with us. Make a one-time contribution to Raw Story Investigates, or click here to become a subscriber. Thank you. Click to donate by check.

then let us make a small request. The COVID crisis has cut advertising rates in half, and we need your help. Like you, we believe in the power of progressive journalism and were investing in investigative reporting as other publications give it the ax. Raw Story readers power David Cay Johnstons DCReport, which we've expanded to keep watch in Washington. Weve exposed billionaire tax evasion and uncovered White House efforts to poison our water. Weve revealed financial scams that prey on veterans, and efforts to harm workers exploited by abusive bosses. We need your support to do what we do.

Raw Story is independent. You wont find mainstream media bias here. Every reader contribution, whatever the amount, makes a tremendous difference. Invest with us in the future. Make a one-time contribution to Raw Story Investigates, or click here to become a subscriber. Thank you.

Read the rest here:
Did this virus come from a lab? Maybe not but it exposes the threat of a biowarfare arms race - Raw Story

Read More...

I’m Sorry, What? – Outside The Beltway – Mobile Edition

April 25th, 2020 7:53 am

Trump made some odd suggestions on today's Al Presidente.

Steven L. Taylor Thursday, April 23, 2020 82 comments

Bloomberg reports: Trump Sees Coronavirus Hope in Summer, Sunlight and Bleach

The virus is dying at a much more rapid pace from exposure to humidity or heat, Bill Bryan, an undersecretary at the Homeland Security Department, said at a White House news conference on Thursday.

[]

Bryan suggested the new U.S. research offered practical tips for many Americans, including increasing the temperature and humidity for potentially contaminated indoor spaces in order to kill the virus on surfaces. At a temperature of 70 to 75 degrees Fahrenheit and 80% humidity in the summer sun, for example, the research showed the virus would last just two minutes on a porous surface. Dry environments Bryan said, may require extra care.

Very Powerful Light

Trump appeared intrigued by the research after Bryans presentation.

Suppose we hit the body with a tremendous ultraviolet or just very powerful light, Trump said, following Bryans presentation. I think that hasnt been checked but youre going to test it.

Researchers could also bring the light inside the body Trump said, either through the skin or in some other way.

[]

Bryan also said that research had shown bleach could kill the virus in saliva or respiratory fluids in five minutes and isopropyl alcohol could kill it even more quickly. Trump suggested there would be more testing there, too.

The disinfectant knocks it out in a minute. One minute, he said. Is there a way we can do something like that by injection inside? He said it would be almost a cleaning. It gets in the lungs and does a tremendous number on the lungs.

(Emphases mine).

In case you cant believe what you just read:

I am not sure which is crazier, the notion that cleaner could be used or light could be put inside the body (although, really, does one have to rank in this case?).

Unlike the President of the United States, the Bloomberg report cautions:

Disinfecting surfaces is an important practice in infection control. The coronavirus is fragile outside the body, and is essentially a packet of genetic information wrapped in a packet of lipids. Hand washing with soap is particularly effective in cleaning it and stopping transmission.

The U.S. Centers for Disease Control and Prevention has warned Americans to be careful with cleaning products in their rush to use cleaners and disinfectants, which have been snapped up from store shelves and are still hard to find at many retailers. Poisonings related to cleaners and disinfectants rose significantly in March, according to the CDC. In one case, a woman was sent to the hospital after filling her sink with bleach solution, vinegar and hot water to soak her vegetables.

He tries to bring Birx into the mix and then note his response when confronted about the whole heat and light thing:

You know, hes just asking. Lighten up!

All of this is, of course, quite bizarre and I am leaning heavily on the absurdity angle (as this is very much a laugh lest you cry situation). But, good grief, we in the middle of a global pandemic with no clear end in sight and with over 44,000 Americans dead, and the president is spitballing light therapy and the potential use of cleaners in the human body to fight Covid-19. And worse, many, many of my fellow Americans think he is doing a good job.

BTW, if we think that heat and humidity will be our salvation, the following story popped up while I was writing this (via the NYT): Ecuadors Death Toll During Outbreak Is Among the Worst in the World.

With bodies abandoned on sidewalks, slumped in wheelchairs, packed into cardboard coffins and stacked by the hundreds in morgues, it is clear that Ecuador has been devastated by the coronavirus.

But the epidemic is even worse than many people in the country realize.The death toll in Ecuador during the outbreak was 15 times higher than the official number of Covid-19 deaths reported by the government, according to an analysis of mortality data by The New York Times.The numbers suggest that the South American country is suffering one of the worst outbreaks in the world.

[]

There has been a surge of infections in the province that includes Ecuadors business capital, Guayaquil, where residents are thought to have brought the virus home after visiting Spain.In Guayaquil, fatalities during the first two weeks of April were eight times higher than usual, the data indicates a far greater rise than that of New York City, where fatalities were four times higher in recent weeks.

Guayaquil has a decidedly tropical climate

PS. Yes, the use of light to kill an infestation was a plot point in the Star Trek TOS episode, Operation: Annihilate:

Read more:
I'm Sorry, What? - Outside The Beltway - Mobile Edition

Read More...

Why biotech’s goal should not be to feed the world – SynBioBeta

April 25th, 2020 7:51 am

Its a great moment for big food, big ag, and industry to do a self reflection and analysis of, how did we arrive here? How did we arrive to a world where the folks that picked the produce out of the field dont have access and or make enough to buy the very produce that theyre picking? Rolando Perez, graduate student and volunteer at Xinampa

Biotechnology is on the precipice of changing our world forever. Using solutions always there in biology and optimizing them with technology, biotech promises to solve global issues such as carbon emissions, plastic and chemical pollution, and, of course, feeding a booming population. But to really solve the issue of food, the industry needs to revolutionize more than just biology or technology. It needs to revolutionize the way it engages local cultures and economies. It will not be an easy task, a straightforward task, or a quick task. But it can be done and the people of the world depend on it being done right.

Climate change and population growth have led to predictions that the global population will reach nearly 10 billion people by 2050. Current food production processes cant keep pace with that growth. Fearing an existential crisis, several companies have adopted a tag line that goes something like this: we will feed the world through innovative biotechnologies that are more sustainable and make healthy food more accessible. And theyve got the sustainability beat down: from leveraging microbes to feed plants and reduce toxic nitrogen run-off to improved aquaculture techniques to genetic engineering foods to be more nutritious, the possibilities for producing ever more nutritious food while using less of the Earths precious resources are boundless and already in motion.

But what, exactly, does it mean for food to be accessible in todays world?

Food desert a term used to describe areas with limited access to affordable and nutritious food is the label by which weve come to describe food accessibility today. But the term is a bit of a misnomer, says Garrett Broad, author of More Than Just Food.

It suggests theres nothing there and if food deserts are the problem, the solution sounds pretty simple: just bring [stuff] to the desert.

But is there really nothing there? According to a recent New York Times exposition on the obesity epidemic in Brazil (and in big industrys role in that), there are now more obese people in the world than underweight people. Its as if the pendulum has swung the other direction where hunger was once a very real problem as a result of access to food, period, now obesity, diabetes, and heart disease prevail as a result of access to high calorie, nutrient-poor foods. This has created a new type of malnutrition, write Andrew Jacobs and Matt Richtel, one in which a growing number of people are both overweight and undernourished.

So, continues Broad, the problem isnt food deserts [per se], the problem is really a legacy and generational disinvestment in and direct discrimination in not just food but in a variety of other arenas. [This] calls for a broader set of solutions.

Said another way, the issue of food accessibility is multi-faceted and therefore cannot be solved solely through biotechnology we must come to terms with that fact at the get go. That isnt to say biotechnology cant make the food production system as a whole better. With advances in gene editing and other technologies, we can use technology to improve the nutritional profile of food (tackling malnutrition), to enable seasonable crops to be available all year round (increasing accessibility in one sense), to remove undesired characteristics such as cherry pits (increasing accessibility in another sense), and to make food more resistant to drought, one of the biggest factors influencing a significant proportion of the world populations access to food. But none of this matters if we keep operating under our current system, which, according to Broad, bottom-lines on profit margins, not on feeding people healthily and sustainably.

The biotechnological revolution can give the food industry and low-income disadvantaged communities a chance to hit the reset button to learn from the current state of affairs and prevent the inevitable shortfall of the big promises being made by biotechnology today if we dont change the societal, political, and economic backbone of the way food is made and distributed. And according to Ana Ibarra and Rolando Perez, volunteers at Salinas Valley-based Xinampa (a bio-hub aiming to support equitable economic development, workforce development, small business incubation, and scientific literacy and education), such sea change will come from getting people from all walks of life to sit down together and talk.

From left: Steven Rhyans, Anna Ibarra-Castro, Leo Tejeda, Omar Perez, Matias Kaplan, Rolando Perez. Photo credit: Steven Rhyans

Many of the communities most affected by food inequality are disadvantaged, underrepresented cultural and ethic groups, such as the Hispanic/Latinx and indigenous populations served by Xinampa. Salinas, California, where Xinampa is based, is over 75% Hispanic or Latinx and it is this population that is the life blood of one of the richest agricultural areas in the world. Xinampa is especially passionate about teaching young people high school and college students how they can use biotechnology in their future careers and to bolster their local communities. Ibarra says that young people will be critical for speeding up the development of technologies, a crucial goal given the issues we have at a global scale to sustain human life in light of climate change, decreasing arable land. The younger generations have the ability and talent to carry this forward, she says, and I believe its crucial to start engagement at a young age.

But, Perez is careful to point out, it isnt just about reaching the young.

The work here is intergenerational, and thats really important. There has to be engagement across the whole intergenerational spectrum the bio belt could be about finding opportunities for retirees to do things in the community plant gardens that produce nutritious produce for the community, for example. The next generation is like the seventh generation. You can say seven generations in the future, seven generations in the past, or you can strategically place yourself in the middle of those seven generations; something I learned from a close friend and that has helped me understand my role as a community member and citizen of our planet.

Emphasizing culture and recognizing that the community as a whole, and in particular indigenous communities, has deep-seeded, critical knowledge about agriculture is a core value of Xinampa. Instead of feeding people the all-too-often heard script of you guys just dont know anything, youre eating unhealthy, and were here to change you, they recognize and encourage the generations of knowledge and cultural richness that will be critical for effectively governing and incorporating biotechnology into our future food systems.

What the most successful groups that work around food at the grassroots level do is they push past those scripts, and they open up some storytelling about peoples cultural histories through food, says Broad, and that allows folks to claim knowledge about food and cooking and agriculture, which makes them much more likely to have ownership in this whole conversation.

And the whole conversation must also engage policy makers, those involved in the public health care system, industry leaders essentially anyone that could be affected by biotechnology.

One of the solutions that we could employ to address these inequities is to look to the expertise of individuals in public health, policy, social welfare, or other disciplines that are exposed to issues through a different lens and can provide a different point of view, says Ibarra, adding that its important to foster interdisciplinary conversation early on. We dont want to miss something. We dont want to invest in a solution that may not be the most effective simply because you forgot to include someone in the conversation. Early engagement is how these nutritious and novel foods will be cultivated from the ground up for the benefit of everyone in society.

One of the reasons early involvement in conversation will enable effective distribution of food to everyone is rooted in money. According to Broad, one of the biggest reasons why mistrust in GMOs and how GMO foods could solve some big problems isnt because companies havent been transparent. Its because people look at the big players, the companies in charge, and see companies that havent made their lives substantively better. People recognize that priorities within the biotech industry have not necessarily always been first and foremost about feeding the world equitably and sustainably but instead about who profits from certain biotechnological developments, says Broad. This erodes trust rather than building it.

A great way to build long standing trust is to have equitable distribution of the material wealth that gets created from these innovations. Essentially, how do we think about the development of these tools in an equitable and inclusive way in terms of economic development and economic opportunity? The best way to do this is to get people involved from early on and give them an economic stake so you develop companies that people are engaged in and involved in. That would be something for entrepreneurs and communities like [SynBioBeta] to be thinking about from an early stage, as opposed to thinking about it as kind of a PR approach that comes at the very end.

Its the economy stupid, he continues. Its that classic line if people can see that their economic and social life is going to benefit from these new innovations, then theyre much more likely to be interested in supporting them and have less fear, he says.

Ibarra agrees.

There is a lot of fear around automation and AI, including in communities like ours where the fear is robots are going to come in and pick produce and there will be less jobs for our laborers, she says. But I think the opportunities deriving from biotechnology have an even greater potential. In Monterey County we have a very robust economy resulting from direct and indirect agricultural jobs, but also a significant multiplier effect. If we couple new agricultural technologies, such as automation and AI, with biotechnology in parallel, you can see this allowing communities especially rural ones to be more resilient. Its a real opportunity.

This is critical for communities like Salinas Valley, where homelessness rates in elementary schools can be as high as 50 percent. According to Ibarra, agricultural communities like Salinas are the perfect place to cultivate regenerative biotechnologies that enrich our food systems and advance public health. She and Perez imagine a future for Salinas Valley completely transformed by biotechnology rooted in racial and class equity and justice. For example, Central Coast residents could create public interest biotechnologies that emphasize community control and governance, with investment in people, infrastructure, automation, and supply-chains that extend into the community and that connect to the Valleys world-class global supply-chains. Biotechnology can also be leveraged to produce nutritious crop varieties that adapt plant morphology to make harvesting by hand easier or gene drives to combat invasive pests such as the Asian Citrus Psyllid. Animal agriculture could benefit as well, with new veterinary biotechnological tools to better care for livestock and protect them from disease. Water systems could benefit as well, from cleaning the Salinas River through mycoremediation to employing biosensors to monitor city water for pollution, pesticides, and other chemicals.

In December 2019, Golden Rice was approved for direct use in the Philippines the first Asian country to grant the controversial food approval. Some expect that the added Vitamin A present in the rice will reduce by up to 50% vitamin A deficiency, the leading cause of child mortality in the country. But, others are skeptical that the rice will be the simple solution Filipinos have been waiting for, pointing out that vitamin A deficiency is a complex problem partially rooted in culture, political economics, education, and access. In essence, Golden Rice is the perfect example of both the promise of biotechnology in agriculture and its shortcomings if we dont think critically about all sides of the issue. With up and coming companies like Pairwise Plants and others using biotechnology to produce food that is more nutritious and can be available year-round, it is critical that we heed voices like Broad, Ibarra, and Perez so that technologies that can really make a difference in how we feed the world dont meet the same fate as Golden Rice.

It is possible to feed the world with biotechnology. But its only possible if our goal isnt to feed the world, but to engage local communities, support early, equitable, and inclusive communication, and to ensure that food equity doesnt just mean that everyone can afford to buy healthy food, but that the communities producing that food have equitable economic stake. Move over, big ag its time to take biotechnology from farm to table.

Read the original post:
Why biotech's goal should not be to feed the world - SynBioBeta

Read More...

Chromatography in Pharmaceuticals and Biotechnology Expansion ( COVID 19-UPDATED ) Projected to Gain an Uptick During 2026 – Cole of Duty

April 25th, 2020 7:51 am

The Chromatography in Pharmaceuticals and Biotechnology Market report shows a brilliant presentation of regional growth, competition and provides accurate statistics with price and gross margin and other essential factors to grow in the Chromatography in Pharmaceuticals and Biotechnology market. The Chromatography in Pharmaceuticals and Biotechnology market report digs deep into critical aspects of key subjects which help market players to make appropriate changes in their approach and help you craft better strategies. The report is made with a combination of detailed information relying upon the important data researched by our analysts.

Chromatography is a continuously evolving technique, and its success is dependent on the innovations in technology. Therefore, this report discusses the emerging trends in chromatography technology, particularly the instruments and the reagents. It also features the new developments and new product launches in the global market.

The report provides relevant patent analyses and comprehensive profiles of market players in the industry. The Industry Structure chapter focuses on the important chromatography instruments and reagent manufacturers and suppliers, their market shares and product offerings. The chapter also covers the mergers and acquisitions and any other collaborations or partnerships that happened during the evaluation period of this report that are expected to shape the industry.

BCCs new report on chromatography elaborates on the strengths, weaknesses, threats and opportunities of the global chromatography market. Any regulatory changes or new initiatives are also highlighted.

Get Sample Copy of this Report @https://www.reportsintellect.com/sample-request/698611

Chromatography in Pharmaceuticals and Biotechnology Market report provides competitive analysis which helps clients to become aware of the unique characteristics of crucial factors impacting the market competition and hence changing their growth potential by manifold. Chromatography in Pharmaceuticals and Biotechnology market report provides accurate market data, market dynamics, and key segments.

Get Discounted Report @https://www.reportsintellect.com/discount-request/698611

Table of Contents:-

Highlights of the worldwide Chromatography in Pharmaceuticals and Biotechnology Market Report:

About us:

Reports Intellect provides research reports for everything related to market research and market intelligence. We understand the importance of the market with its needs in todays competitive world.

Our team works to obtain the most authentic research reports, accompanied by perfect data figures which guarantee exceptional results for you and your company every time.

Our team is there to help you in the best possible way, whether it is the latest report from the researchers or a personalized requirement, do not hesitate to contact us.

Contact us:

[emailprotected]

PH + 1-706-996-2927

US Address:

225 Peachtree Street NE,

Suite 400,

Atlanta, GA 30303

The rest is here:
Chromatography in Pharmaceuticals and Biotechnology Expansion ( COVID 19-UPDATED ) Projected to Gain an Uptick During 2026 - Cole of Duty

Read More...

Global Animal Stem Cell Therapy Market 2020 Future Scenario, Industry Growth Insights and Production Analysis 2025 – Bandera County Courier

April 25th, 2020 7:50 am

Mrinsights.bizhas published a new report titled GlobalAnimal Stem Cell TherapyMarketGrowth 2020-2025 which comprises new statistical data on the changing market scenario and initial and future assessment of the market. The report covers a wide range of business aspects global Animal Stem Cell Therapy trends, future forecasts, growth opportunities, key end-user industries, and market players. The report analyzes the recent developments, investment opportunities, and probable threats in the market. It closely looks at the markets all-purpose evaluation and depicts the important data associated with the global market.

DOWNLOAD FREE SAMPLE REPORT:https://www.mrinsights.biz/report-detail/232664/request-sample

The report assesses the demand-side and supply-side trends in the global Animal Stem Cell Therapy market. Various segments are scrutinized that involve end-users, regions, and players on the basis of demand patterns, and prospect for 2020 to 2025 time-period. The research report contains a comprehensive database on future market estimation based on historical data analysis. Key players are listed with major collaborations, mergers & acquisitions and upcoming and trending innovation. Primary research involves interviews, news sources and information booths. Secondary research techniques add more in clear and concise understanding with regards to placing of data in the report.

Understanding The Competitive Scenario:

Competitive landscape analysis is presented which involves the global Animal Stem Cell Therapy market share of major players, along with the new projects and strategies adopted by players in the past five years. Comprehensive company profiles comprise the product offerings, key financial information, recent developments, SWOT analysis, capacity, production, price, revenue, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, and strategies employed by the major market players. Additionally, the report covers insights into the production and capacities in terms of manufacturing with price fluctuations of raw materials, process in-flow rate product cost, and production value.

Considering market analysis, the profiled list of companies in the report is:Medivet Biologics LLC, Animal Cell Therapies, VETSTEM BIOPHARMA, U.S. Stem Cell, Inc, VetCell Therapeutics, J-ARM, Kintaro Cells Power, Celavet Inc., Animal Stem Care, Magellan Stem Cells, Cell Therapy Sciences, Animacel

Currently, the research report gives special attention and focus on the following regions:Americas (United States, Canada, Mexico, Brazil), APAC (China, Japan, Korea, Southeast Asia, India, Australia), Europe (Germany, France, UK, Italy, Russia, Spain), Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries).

Moreover, the report identifies potential customers and suppliers as well as gives an analysis of the companys business structure, operations, major products and services, and business strategy. The study helps you understand the companys core strengths, weaknesses, opportunities, and threats. The report shows factual data about the global Animal Stem Cell Therapy market in the worldwide area, for example, production chain, manufacturing capacity, sales volume, and revenue.

ACCESS FULL REPORT:https://www.mrinsights.biz/report/global-animal-stem-cell-therapy-market-growth-2020-2025-232664.html

The Scope of The Global Animal Stem Cell Therapy Report:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@mrinsights.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

The rest is here:
Global Animal Stem Cell Therapy Market 2020 Future Scenario, Industry Growth Insights and Production Analysis 2025 - Bandera County Courier

Read More...

Animal Stem Cell Therapy Market Is Set To Experience Revolutionary Growth By 2025 – Cole of Duty

April 25th, 2020 7:50 am

The Animal Stem Cell Therapy report provides independent information about the Animal Stem Cell Therapy industry supported by extensive research on factors such as industry segments size & trends, inhibitors, dynamics, drivers, opportunities & challenges, environment & policy, cost overview, porters five force analysis, and key companies profiles including business overview and recent development.

Animal Stem Cell Therapy MarketLatest Research Report 2020:

Download Premium Sample Copy Of This Report: Download FREE Sample PDF!

In this report, our team offers a thorough investigation of Animal Stem Cell Therapy Market, SWOT examination of the most prominent players right now. Alongside an industrial chain, market measurements regarding revenue, sales, value, capacity, regional market examination, section insightful information, and market forecast are offered in the full investigation, and so forth.

Scope of Animal Stem Cell Therapy Market: Products in the Animal Stem Cell Therapy classification furnish clients with assets to get ready for tests, tests, and evaluations.

Animal Stem Cell Therapy Market Report Covers the Following Segments:

Segment1: By Type, Dogs, Horses, Others, By Application, Veterinary Hospitals, Research Organizations

Market Overview:The report begins with this section where product overview and highlights of product and application segments of the global Animal Stem Cell Therapy Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company:Here, the competition in the Worldwide Animal Stem Cell Therapy Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global Animal Stem Cell Therapy Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Animal Stem Cell Therapy Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Animal Stem Cell Therapy Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global Animal Stem Cell Therapy Market.

Market Forecast:Here, the report offers a complete forecast of the global Animal Stem Cell Therapy Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Top Trending Reports:

https://www.marketwatch.com/press-release/at-1905-cagr-pop-up-cinema-market-size-to-surpass-us-197229-million-by-2025-2020-04-24

https://www.marketwatch.com/press-release/at-1905-cagr-pop-up-cinema-market-size-to-surpass-us-197229-million-by-2025-2020-04-24

https://www.marketwatch.com/press-release/ipaas-integration-platform-as-a-service-market-size-share-application-analysis-regional-outlook-growth-trends-top-key-players-and-competitive-strategiesforecast-to-2025-2020-04-24?tesla=y

https://www.marketwatch.com/press-release/microwave-transmission-equipment-market-2020-share-trends-segmentation-and-forecast-by-2025-cagr-of-314-2020-04-24-61763810?tesla=y

http://marketwatch.com/press-release/military-drone-market-share-size-future-demand-global-research-top-leading-player-emerging-trends-region-by-forecast-to-2025-2020-04-24?tesla=y

Read the original here:
Animal Stem Cell Therapy Market Is Set To Experience Revolutionary Growth By 2025 - Cole of Duty

Read More...

Global Cell Sorting Market 2020 Industry Analysis by Manufacturers, Type, Application, End-User and Forecast 2025 – Bandera County Courier

April 25th, 2020 7:50 am

A new research study titled Global Cell Sorting Market Report 2020, Forecast to 2025 has been presented by Magnifier Research which offers a comprehensive analysis on the market. Users can benefit from this complete market research report with all the required useful information about this market. The report covers the important components related to the top sellers of the global Cell Sorting industry that influence the market. However, it inspects the primary formats changing the dynamics of the market. Likewise, it covers related current affairs, which will be influencing the market. What more, it simplifies the essential sections and also the sub-sections that represents the recent zone.

Key Components Covered in The Report:

The research document is a detailed study on the growth, investment opportunities, market statistics, growing competition analysis, major key players, industry facts, important figures, sales, prices, revenues, gross margins, market shares, business strategies, top regions, demand, and developments. The report further estimates the global Cell Sorting industry esteem chain, powerful business strategies, cost, structure, creation limit, conveyance, market range, and limits usage rate. The market provides basic information of market members and organizing profiling, contact data, item/benefit beds, income development, revenue generation, and gross deals. This study also provides sales, revenue, and market share for each player covered in this report for a period between 2015 and 2020.

DOWNLOAD FREE SAMPLE REPORT: https://www.magnifierresearch.com/report-detail/37752/request-sample

Following are the topmost key players covered in this global Cell Sorting market research report:- NanoCellect Biomedical, Innovative Biochips, Cesca Therapeutics, Fluidigm, LumaCyte, Union Biometrica, LevitasBio, RareCyte, Cytonome, Namocell, STEMCELL Technologies, Akadeum Life Sciences

Together with geography at the worldwide forecast to 2025 is just absolutely professional and thorough. Moreover, the research study lists the major regional countries, focusing on the remarkable regions:- North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa).

The market segment based on product type includes:- Cancer Cell, Immune Cells, Microbial Cell, Red Blood Cell/Platelet, Stem Cell, Other

Applications mentioned in this report:- Cell Research, Biomedical Diagnosis, Other

Furthermore, the global Cell Sorting market has been divided into types, applications, and regions. This data provides a detailed and accurate country-wise volume analysis and region-wise market size analysis of the global market. The report further includes market shares for 2015 and 2025, for each of the above-mentioned segments. It also highlights the export and import of the market. It also analyses the regional distribution of the industry in terms of development trends.

ACCESS FULL REPORT: https://www.magnifierresearch.com/report/global-cell-sorting-market-report-2020-forecast-to-37752.html

Points Covered In This Report:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@magnifierresearch.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Magnifier Research is a leading market intelligence company that sells reports of top publishers in the technology industry. Our extensive research reports cover detailed market assessments that include major technological improvements in the industry. Magnifier Research also specializes in analyzing hi-tech systems and current processing systems in its expertise. We have a team of experts that compile precise research reports and actively advise top companies to improve their existing processes. Our experts have extensive experience in the topics that they cover. Magnifier Research provides you the full spectrum of services related to market research, and corroborate with the clients to increase the revenue stream, and address process gaps.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@magnifierresearch.comWeb: http://www.magnifierresearch.com

See more here:
Global Cell Sorting Market 2020 Industry Analysis by Manufacturers, Type, Application, End-User and Forecast 2025 - Bandera County Courier

Read More...

Stem Cell Therapy Market Overview by 2026: Verified Market Research – Cole of Duty

April 25th, 2020 7:50 am

Allosource

Global Stem Cell Therapy Market Segmentation

This market was divided into types, applications and regions. The growth of each segment provides an accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting niche markets. Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, the Asia-Pacific region, the Middle East, and Africa and Latin America. Research analysts understand the competitive forces and provide competitive analysis for each competitor separately.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=COD&utm_medium=002

Global Stem Cell Therapy Market Regions and Countries Level Analysis

The regional analysis is a very complete part of this report. This segmentation highlights Stem Cell Therapy sales at regional and national levels. This data provides a detailed and accurate analysis of volume by country and an analysis of market size by region of the world market.

The report provides an in-depth assessment of growth and other aspects of the market in key countries such as the United States, Canada, Mexico, Germany, France, the United Kingdom, Russia and the United States Italy, China, Japan, South Korea, India, Australia, Brazil and Saudi Arabia. The chapter on the competitive landscape of the global market report contains important information on market participants such as business overview, total sales (financial data), market potential, global presence, Stem Cell Therapy sales and earnings, market share, prices, production locations and facilities, products offered and applied strategies. This study provides Stem Cell Therapy sales, revenue, and market share for each player covered in this report for a period between 2016 and 2020.

Why choose us:

We offer state of the art critical reports with accurate information about the future of the market.

Our reports have been evaluated by some industry experts in the market, which makes them beneficial for the company to maximize their return on investment.

We provide a full graphical representation of information, strategic recommendations and analysis tool results to provide a sophisticated landscape and highlight key market players. This detailed market assessment will help the company increase its efficiency.

The dynamics of supply and demand shown in the report offer a 360-degree view of the market.

Our report helps readers decipher the current and future constraints of the Stem Cell Therapy market and formulate optimal business strategies to maximize market growth.

Table of Contents:

Study Coverage: It includes study objectives, years considered for the research study, growth rate and Stem Cell Therapy market size of type and application segments, key manufacturers covered, product scope, and highlights of segmental analysis.

Executive Summary: In this section, the report focuses on analysis of macroscopic indicators, market issues, drivers, and trends, competitive landscape, CAGR of the global Stem Cell Therapy market, and global production. Under the global production chapter, the authors of the report have included market pricing and trends, global capacity, global production, and global revenue forecasts.

Stem Cell Therapy Market Size by Manufacturer: Here, the report concentrates on revenue and production shares of manufacturers for all the years of the forecast period. It also focuses on price by manufacturer and expansion plans and mergers and acquisitions of companies.

Production by Region: It shows how the revenue and production in the global market are distributed among different regions. Each regional market is extensively studied here on the basis of import and export, key players, revenue, and production.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=COD&utm_medium=002

We also offer customization on reports based on specific client requirement:

1- Free country level analysis for any 5 countries of your choice.

2- Free Competitive analysis of any market players.

3- Free 40 analyst hours to cover any other data points

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes, Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Tags: Stem Cell Therapy Market Size, Stem Cell Therapy Market Trends, Stem Cell Therapy Market Forecast, Stem Cell Therapy Market Growth, Stem Cell Therapy Market Analysis

Continue reading here:
Stem Cell Therapy Market Overview by 2026: Verified Market Research - Cole of Duty

Read More...

Cover Corona Outbreak: Hematologic Malignancies Market is expected to grow at a CAGR of xx% during the forecast period from 2019-2025 – Cole of Duty

April 25th, 2020 7:50 am

Hematologic Malignancies MarketLatest Research Report 2020:

The Hematologic Malignancies report provides an independent information about the Hematologic Malignancies industry supported by extensive research on factors such as industry segments size & trends, inhibitors, dynamics, drivers, opportunities & challenges, environment & policy, cost overview, porters five force analysis, and key companies

Download Premium Sample Copy Of This Report:Download FREE Sample PDF!

In this report, our team offers a thorough investigation of Hematologic Malignancies Market, SWOT examination of the most prominent players right now. Alongside an industrial chain, market measurements regarding revenue, sales, value, capacity, regional market examination, section insightful information, and market forecast are offered in the full investigation, and so forth.

Scope of Hematologic Malignancies Market: Products in the Hematologic Malignancies classification furnish clients with assets to get ready for tests, tests, and evaluations.

Major Company Profiles Covered in This Report

Pfizer, Inc., F. Hoffmann-LA Roche ltd, Sanofi-Aventis, Bristol-Myers Squibb Company, AbbVie, Inc., Novartis AG, GlaxoSmithKline PLC, Celgene Corporation, Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company limited,

Hematologic Malignancies Market Report Covers the Following Segments:<

Market segment by Type, the product can be split into

Leukemia, Lymphoma, Multiple Myeloma, Others,

Market segment by Application, split into

Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation, Others,

Market segment by Regions/Countries, this report covers

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia and Turkey etc.)

Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)

South America (Brazil etc.)

Middle East and Africa (Egypt and GCC Countries)

North America

Europe

Asia-Pacific

South America

Center East and Africa

United States, Canada and Mexico

Germany, France, UK, Russia and Italy

China, Japan, Korea, India and Southeast Asia

Brazil, Argentina, Colombia

Saudi Arabia, UAE, Egypt, Nigeria and South Africa

Market Overview:The report begins with this section where product overview and highlights of product and application segments of the global Hematologic Malignancies Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company:Here, the competition in the Worldwide Hematologic Malignancies Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global Hematologic Malignancies Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Hematologic Malignancies Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Hematologic Malignancies Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global Hematologic Malignancies Market.

Market Forecast:Here, the report offers a complete forecast of the global Hematologic Malignancies Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Read the original:
Cover Corona Outbreak: Hematologic Malignancies Market is expected to grow at a CAGR of xx% during the forecast period from 2019-2025 - Cole of Duty

Read More...

Global IT Outsourcing Managed Service Market 2020: COVID 19 Breakdown Impact, Industry Analysis, Players, Type, Applications, Size, Share, Growth,…

April 25th, 2020 7:50 am

In Global IT Outsourcing Managed Service Market Research Report, the study analysis was given on a worldwide scale, for instance, present and traditional IT Outsourcing Managed Service growth analysis, competitive analysis, and also the growth prospects of the central regions. The report gives an exhaustive investigation of this market provides an analysis of the industry trends in each of the sub-segments, from sales, revenue and consumption. A quantitative and qualitative analysis of the main players in Global and country level is introduced, from the perspective of sales, revenue and price.

Request a sample of IT Outsourcing Managed Service Market report @https://martresearch.com/contact/request-sample/5/32559

Snapshot:The global IT Outsourcing Managed Service market size is estimated at xxx million USD with a CAGR xx% from 2015-2019 and is expected to reach xxx Million USD in 2020 with a CAGR xx% from 2020 to 2025. The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of IT Outsourcing Managed Service by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.

Product Type Coverage(Market Size & Forecast, Major Company of Product Type etc.):

IT ConsultingEquipment And SoftwareNetwork SystemOthers

Company Coverage(Company Profile, Sales Revenue, Price, Gross Margin, Main Products etc.):

IBMAccentureWiproCognizantDXC TechnologiesHCLHPInfosysCapgeminiNTT DataCGISAP

Application Coverage(Market Size & Forecast, Different Demand Market by Region, Main Consumer Profile etc.):

Traditional IndustryHigh TechOthers

Region Coverage(Regional Production, Demand & Forecast by Countries etc.):

North America (U.S., Canada, Mexico)Europe (Germany, U.K., France, Italy, Russia, Spain etc.)Asia-Pacific (China, India, Japan, Southeast Asia etc.)South America (Brazil, Argentina etc.)Middle East & Africa (Saudi Arabia, South Africa etc.)

At the upcoming section, this report discusses industrial policy, economic environment, in addition cost structures of the industry. And this report encompasses the fundamental dynamics of the market which include drivers, opportunities, and challenges faced by the industry. Additionally, this report showed a keen market study of the main consumers, raw material manufacturers and distributors, etc.

Buy The Report @https://martresearch.com/paymentform/5/32559/Single_User

Major Point of TOC:

Table of Content1 Industry Overview2 Industry Environment (PEST Analysis)3 IT Outsourcing Managed Service Market by Type4 Major Companies List5 Market Competition6 Demand by End Market7 Region Operation8 Marketing & Price9 Research Conclusion

About us:Research is and will always be the key to success and growth for any industry. Most organizations invest a major chunk of their resources viz. time, money and manpower in research to achieve new breakthroughs in their businesses. The outcome might not always be as expected thereby arising the need for precise, factual and high-quality data backing your research. This is where MART RESEARCH steps in and caters its expertise in the domain of market research reports to industries across varied sectors.

Contact Us:

Mart Research[emailprotected]+1-857-300-1122

Link:
Global IT Outsourcing Managed Service Market 2020: COVID 19 Breakdown Impact, Industry Analysis, Players, Type, Applications, Size, Share, Growth,...

Read More...

Cell Isolation/Cell Separation Market 2020: Opportunities in Grooming Regions Thermo Fisher Scientific, Merck Millipore, Beckman Coulter and Others -…

April 25th, 2020 7:50 am

Futuristic Reports, The growth and development of Global Cell Isolation/Cell Separation Market Report 2020 by Players, Regions, Type, and Application, forecast to 2026 provides industry analysis and forecast from 2020-2026. Global Cell Isolation/Cell Separation Market analysis delivers important insights and provides a competitive and useful advantage to the pursuers. Cell Isolation/Cell Separation processes, economic growth is analyzed as well. The data chart is also backed up by using statistical tools.

Simultaneously, we classify different Cell Isolation/Cell Separation markets based on their definitions. Downstream consumers and upstream materials scrutiny are also carried out. Each segment includes an in-depth explanation of the factors that are useful to drive and restrain it.

Key Players Mentioned in the study are Thermo Fisher Scientific, Merck Millipore, Beckman Coulter, Stemcell Technologies, Pluriselect Life Science, Miltenyi Biotec, GE Healthcare, BD Bioscience, Terumo BCT

For Better Understanding, Download FREE Sample Copy of Cell Isolation/Cell Separation Market Report @ https://www.futuristicreports.com/request-sample/3907

Key Issues Addressed by Cell Isolation/Cell Separation Market: It is very significant to have Cell Isolation/Cell Separation segmentation analysis to figure out the essential factors of growth and development of the market in a particular sector. The Cell Isolation/Cell Separation report offers well summarized and reliable information about every segment of growth, development, production, demand, types, application of the specific product which will be useful for players to focus and highlight on.

Businesses Segmentation of Cell Isolation/Cell Separation Market:

On the basis on the applications, this report focuses on the status and Cell Isolation/Cell Separation outlook for major applications/end users, sales volume, and growth rate for each application, including-

Biotechnology Research Center Hospital Others

On the basis of types/products, this Cell Isolation/Cell Separation report displays the revenue (Million USD), product price, market share, and growth rate of each type, split into-

Instrument Reagent Others

Grab Best Discount on Cell Isolation/Cell Separation Market Research Report [Single User | Multi User | Corporate Users] @ https://www.futuristicreports.com/check-discount/3907

NOTE: Our team is studying Covid-19 impact analysis on various industry verticals and Country Level impact for a better analysis of markets and industries. The 2020 latest edition of this report is entitled to provide additional commentary on latest scenario, economic slowdown and COVID-19 impact on overall industry. Further it will also provide qualitative information about when industry could come back on track and what possible measures industry players are taking to deal with current situation.

OR

You just drop an Email to:[emailprotected] us if you are looking for any Economical shift towards the New Normal on any Country or Industry Verticals.

Cell Isolation/Cell Separation Market Regional Analysis Includes:

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) North America (the United States, Mexico, and Canada.) South America (Brazil etc.) The Middle East and Africa (GCC Countries and Egypt.)

Cell Isolation/Cell Separation Insights that Study is going to provide:

Gain perceptive study of this current Cell Isolation/Cell Separation sector and also possess a comprehension of the industry; Describe the Cell Isolation/Cell Separation advancements, key issues, and methods to moderate the advancement threats; Competitors In this chapter, leading players are studied with respect to their company profile, product portfolio, capacity, price, cost, and revenue. A separate chapter on Cell Isolation/Cell Separation market structure to gain insights on Leaders confrontational towards market [Merger and Acquisition / Recent Investment and Key Developments] Patent Analysis** Number of patents filed in recent years.

Table of Content:

Global Cell Isolation/Cell Separation Market Size, Status and Forecast 20261. Market Introduction and Market Overview2. Industry Chain Analysis3. Cell Isolation/Cell Separation Market, by Type4. Cell Isolation/Cell Separation Market, by Application5. Production, Value ($) by Regions6. Production, Consumption, Export, Import by Regions (2016-2020)7. Market Status and SWOT Analysis by Regions (Sales Point)8. Competitive Landscape9. Analysis and Forecast by Type and Application10. Channel Analysis11. New Project Feasibility Analysis12. Market Forecast 2020-202613. Conclusion

Enquire More Before Buying @ https://www.futuristicreports.com/send-an-enquiry/3907

For More Information Kindly Contact:

Futuristic ReportsTel: +1-408-520-9037Media Release:https://www.futuristicreports.com/press-releases

Follow us on Blogger @https://futuristicreports.blogspot.com/

See more here:
Cell Isolation/Cell Separation Market 2020: Opportunities in Grooming Regions Thermo Fisher Scientific, Merck Millipore, Beckman Coulter and Others -...

Read More...

Bayer, Novartis, and Trump convicted by Nature – European Biotechnology

April 24th, 2020 5:49 pm

The politically overhyped use of old malaria drugs in combination with COVID-19-specific candidates has been demonstrated to be dangerous, reports Nature Medicine.

In the prestigous paper Nature Medicine, cardiologists under Lior Jankelson report that patients with COVID-19 who were on a regimen of Novartis AGs generic malaria drug hydroxychloroquine and the antibiotic azithromycin experienced electrocardiogram abnormalities. Previous reports demonstrated that the same is true for chloroquine phosphate, an old malaria drug originally developed at Bayer AG. The authorsassessed 84 patients with COVID-19 treated at a centre in New York, USA.

Azithromycin in combination with antimalarial hydroxychloroquine has been touted by President Donald Trump as a possible "game changer" in COVID-19. Former BARDA head Rick Bright was fired because he resisted political interventions to push the use of chloroquine derivatives to treat COVID-19 despite scientific evidence of efficacy and safety according to current authorisation standards. Biocentury reported previously that Trumps preference for the cheap but antiquated malaria treatments looked more like political science than actually based on scientific evidence. Several clinical programmes coordinated by the WHO , the European Union, and the UK promote clinical testing of combinations with either chloroquine phosphate or hydroxychloroquine and may cause thousands of deaths unless they were not updated to include new findings.

Several reports demonstrated that both medications increase the risk of various types of cardiac rhythm abnormalities, such as QTc-interval prolongation and drug-inducedtorsades de pointes, and sudden cardiac death. The QTc interval is measured by an electrocardiogram and represents the time it takes for a heart to recharge between beats. A prolonged QTc interval puts a patient at risk for arrhythmia and sudden cardiac death.

Now, Jankelson and colleagues reviewed the charts and followed the QTc interval of 84 patients with COVID-19 on a 5-day oral regiment of hydroxychloroquine and azithromycin. The patients were, on average, 63 years of age and74% were male. After the patients were administered the drugs, the authors followed up with an electrocardiogram. They observed a prolonged QTc in most patients. The QTc was severely prolonged in 11% of the patients, which put them at high risk of arrhythmia and sudden cardiac death. Four patients in the cohort died from multiple organ failure a characteristic of septic shock without evidence of arrhythmia and without severe QTc prolongation.

Jankelson and colleagues found that most patients with COVID-19 who were treated with hydroxychloroquine and azithromycin experienced QTc prolongation. This may have been exacerbated by other pre-existing conditions and the severity of the SARS-CoV-2 infection. The authors conclude that the QTc in patients with COVID-19 who are treated with hydroxychloroquine and azithromycin should be monitored constantly, especially for patients with additional illnesses and those who are being treated with other QT-prolonging medications.

Continue reading here:
Bayer, Novartis, and Trump convicted by Nature - European Biotechnology

Read More...

Trends of Biotechnology Separation Systems Market Reviewed for 2020 with Industr – News.MarketSizeForecasters.com

April 24th, 2020 5:49 pm

The ' Biotechnology Separation Systems market' research report is latest addition by Market Study Report, LLC, that elucidates relevant market and competitive insights as well as regional and consumer information. In a nutshell, the research study covers every pivotal aspect of this business sphere that influences the existing trends, profitability position, market share, market size, regional valuation, and business expansion plans of key players in the Biotechnology Separation Systems market.

The latest report on the Biotechnology Separation Systems market is a depiction of the end-to-end analysis of this business vertical, and includes quite some information about the industry, with respect to pivotal parameters such as the most recent market tendencies, present revenue, market share, market size, periodic deliverables, and profits estimations for the forecast period.

Request a sample Report of Biotechnology Separation Systems Market at:https://www.marketstudyreport.com/request-a-sample/2484141?utm_source=marketsizeforecaster.com&utm_medium=TS

A brief overview of how the Biotechnology Separation Systems market will perform over the projected timeframe has been given in the report. Also, details about the driving aspects influencing the market dynamics as well as the growth rate that the industry is expected to register over the forecast duration have been delivered. Additionally, the Biotechnology Separation Systems market report also delivers a brief of the challenges that this vertical is defined by, in conjunction with the growth opportunities that this business space is remnant of.

Main pointers highlighted in the Biotechnology Separation Systems market report:

Unveiling the Biotechnology Separation Systems market with regards to the regional terrain:

Biotechnology Separation Systems Market Segmentation: USA, Europe, Japan, China, India, South East Asia.

A gist of the details presented in the market report with regards to the major industry indicators:

Ask for Discount on Biotechnology Separation Systems Market Report at:https://www.marketstudyreport.com/check-for-discount/2484141?utm_source=marketsizeforecaster.com&utm_medium=TS

A comprehensive gist of the Biotechnology Separation Systems market with regards to the product and application spectrums:

Product landscape:

Product types: Membrane Filtration, Liquid Chromatography, Centrifuge, Electrophoresis, Flow Cytometry and Others

Key insights presented in the report:

Application landscape:

Application segmentation: Commercial and Scientific Research

Specifics provided in the report:

Other major pointers included in the report:

Some details about the competitive terrain of the Biotechnology Separation Systems market include:

Vendor base of the industry: Danaher, Sartorius Stedim Biotech, Thermo Fisher Scientific, Merck, GE Healthcare, BD, Alfa Wassermann, Agilent, Shimadzu, Sysmex, Bio-Rad Laboratories, PerkinElmer, Alfa Laval, Illumina, 3M Purification, Novasep, Hitachi Koki, Affymetrix, Waters and Repligen

Competitive analysis parameters enlisted in the report include:

The Biotechnology Separation Systems market evaluation exhibits substantial details about the aspects like market concentration ratio.

For More Details On this Report: https://www.marketstudyreport.com/reports/global-biotechnology-separation-systems-market-growth-2020-2025

Some of the Major Highlights of TOC covers:

Development Trend of Analysis of Biotechnology Separation Systems Market

Marketing Channel

Market Dynamics

Methodology/Research Approach

Related Reports:

2. Global Low-Earth Orbit Satellite Market Growth 2020-2025Low-Earth Orbit Satellite Market report characterize imperative Portion and contenders of the market regarding market estimate, volume, esteem. This report likewise covers every one of the locales and nations of the world, which demonstrates a territorial improvement status, it additionally incorporates Business Profile, Introduction, Revenue and so on.Read More: https://www.marketstudyreport.com/reports/global-low-earth-orbit-satellite-market-growth-2020-2025

Read More Reports On: https://www.marketwatch.com/press-release/military-laser-systems-market-analysis-with-key-players-applications-trends-and-forecast-to-2025-2020-04-24

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email:

Continued here:
Trends of Biotechnology Separation Systems Market Reviewed for 2020 with Industr - News.MarketSizeForecasters.com

Read More...

Is SAGE Therapeutics Inc (SAGE) Stock Near the Top of the Biotechnology Industry? – InvestorsObserver

April 24th, 2020 5:49 pm

A rating of 18 puts SAGE Therapeutics Inc (SAGE) near the bottom of the Biotechnology industry according to InvestorsObserver. SAGE Therapeutics Inc's score of 18 means it scores higher than 18% of stocks in the industry. SAGE Therapeutics Inc also received an overall rating of 35, putting it above 35% of all stocks. Biotechnology is ranked 10 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

SAGE Therapeutics Inc (SAGE) stock is trading at $38.00 as of 1:22 PM on Friday, Apr 24, a rise of $1.76, or 4.86% from the previous closing price of $36.24. The stock has traded between $35.62 and $38.03 so far today. Volume today is light. So far 545,172 shares have traded compared to average volume of 1,562,765 shares.

To see InvestorsObserver's Sentiment Score for SAGE Therapeutics Inc click here.

Go here to see the original:
Is SAGE Therapeutics Inc (SAGE) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Read More...

Will These Thrive Or Dive ? Vir Biotechnology (VIR), Pinnacle Financial Partners (PNFP) – US Post News

April 24th, 2020 5:49 pm

The recent performance of Vir Biotechnology (NASDAQ:VIR) stock in the market spoke loud and clear to investors as VIR saw more than 1.13M shares in trading volumes in the last trading session, way higher than the average trading volume of 1.13M shares by far recorded in the movement of Vir Biotechnology (VIR). At the time the stock opened at the value of $29.55, making it a high for the given period, the value of the stock jumped by 3.56%. After the increase, VIR touched a low price of $29.55, calling it a day with a closing price of $30.08, which means that the price of VIR went 1.6 below the opening price on the mentioned day.

Given the most recent momentum in the market in the price movement of VIR stock, some strong opinions on the matter of investing in the companys stock started to take shape, which is how analysts are predicting an estimated price of $34.33 for VIR within consensus. The estimated price would demand a set of gains in total of -37.91%, which goes higher than the most recent closing price, indicating that the stock is in for bullish trends. Other indicators are hinting that the stock could reach an outstanding figure in the market share, which is currently set at 100.45M in the public float and 3.41B US dollars in market capitalization.

When it comes to the technical analysis of VIR stock, there are more than several important indicators on the companys success in the market, one of those being the Relative Strength Indicator (RSI), which can show, just as Stochastic measures, what is going on with the value of the stock beneath the data. This value may also indicate that the stock will go sideways rather than up or down, also indicating that the price could stay where it is for quite some time. When it comes to Stochastic reading, VIR stock are showing 26.08% in results, indicating that the stock is neither overbought or oversold at the moment, providing it with a neutral within Stochastic reading as well. Additionally, VIR with the present state of 200 MA appear to be indicating bullish trends within the movement of the stock in the market. While other metrics within the technical analysis are due to provide an outline into the value of VIR, the general sentiment in the market is inclined toward positive trends.

With the previous 100-day trading volume average of 543315 shares, Pinnacle Financial Partners (PNFP) recorded a trading volume of 717220 shares, as the stock started the trading session at the value of $34.35, in the end touching the price of $34.88 after jumping by 1.54%.

PNFP stock seem to be going ahead the lowest price in the last 52 weeks with the latest change of 25.47%.Then price of PNFP also went backward in oppose to its average movements recorded in the previous 20 days. The price volatility of PNFP stock during the period of the last months recorded 6.96%, whilst it changed for the week, now showing 5.92% of volatility in the last seven days. The trading distance for this period is set at -7.95% and is presently away from its moving average by -22.96% in the last 50 days. During the period of the last 5 days, PNFP stock lost around -2.84% of its value, now recording a dip by -37.07% reaching an average $55.32 in the period of the last 200 days.During the period of the last 12 months, Pinnacle Financial Partners (PNFP) dropped by -45.50%.

According to the Barcharts scale, the companys consensus rating was unchanged to 4.00 from 4.00, showing an overall improvement during the course of a single month. Based on the latest results, analysts are suggesting that the target price for PNFP stock should be $34.88 per share in the course of the next 12 months. To achieve the target price as suggested by analysts, PNFP should have a spike by 0% in oppose to its present value in the market. Additionally, the current price showcases a discount of 34.19% when compared to the high consensus price target predicted by analysts.

PNFP shares recorded a trading volume of 588569 shares, compared to the volume of 638.57K shares before the last close, presented as its trading average. With the approaching 5.92% during the last seven days, the volatility of PNFP stock remained at 6.96%. During the last trading session, the lost value that PNFP stock recorded was set at the price of $34.88, while the lowest value in the last 52 weeks was set at $27.80. The recovery of the stock in the market has notably added 25.47% of gains since its low value, also recording -0.11% in the period of the last 1 month.

See original here:
Will These Thrive Or Dive ? Vir Biotechnology (VIR), Pinnacle Financial Partners (PNFP) - US Post News

Read More...

Page 581«..1020..580581582583..590600..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick